S&P 500 Futures Steady in Premarket Trading; United Therapeutics, Tempus AI Lead
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2024
0mins
Source: Barron's
Market Performance: United Therapeutics Corp. and Tempus AI Inc. saw significant pre-market gains of 7.3% and 4.1%, respectively, while Estee Lauder and Landstar System experienced declines of 4.8% and 3.5%. S&P 500 futures were slightly up by 0.02%, contrasting with a slight drop in Dow futures.
Commodities and Global Markets: Brent crude oil and gold futures fell by 0.78% and 0.45%, respectively, while Bitcoin decreased by 2.83%. Asian markets showed mixed results, with Japan's NIKKEI down 1.77% and China's Shanghai Composite up 0.49%, while European stocks also displayed mixed performance.
Analyst Views on EL
Wall Street analysts forecast EL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EL is 106.76 USD with a low forecast of 70.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
8 Buy
9 Hold
1 Sell
Moderate Buy
Current: 119.490
Low
70.00
Averages
106.76
High
130.00
Current: 119.490
Low
70.00
Averages
106.76
High
130.00
About EL
The Estee Lauder Companies Inc. is a manufacturer, marketer and seller of skin care, makeup, fragrance and hair care products. Its product categories include skin care, makeup, fragrance, hair care and others. Its products are sold in approximately 150 countries and territories under a number of brand names, including Estee Lauder, Aramis, Clinique, Lab Series, Origins, M.A.C, Bobbi Brown Cosmetics, La Mer, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frederic Malle, GLAMGLOW, Kilian Paris, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD. It is a licensee for fragrances, cosmetics and/or related products for AERIN, BALMAIN, and Dr. Andrew Weil. Its skin care products include moisturizers, serums, cleansers, toners, exfoliators, facial masks, body care, sun care products and others. Its makeup products include lipsticks, lip glosses, mascaras, foundations and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
